osteogenic-growth-peptide and Thrombocythemia--Essential

osteogenic-growth-peptide has been researched along with Thrombocythemia--Essential* in 1 studies

Other Studies

1 other study(ies) available for osteogenic-growth-peptide and Thrombocythemia--Essential

Article	Year
Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia. Leukemia research, 2004, Volume: 28, Issue:10 The increase of megakaryocytes and platelets that characterizes essential thrombocythemia (ET) appears to be secondary to a deregulation of megakaryocytopoiesis. The carboxy-terminal fragment of osteogenic growth peptide (OGP10-14) promotes bone formation and hemopoiesis, while it inhibits megakaryocytopoiesis. In this paper we show that treatment with synthetic OGP10-14 (sOGP10-14) induces a significant reduction of mid and large colony-forming unit-megakaryocytes (CFU-Mk) in ET patients as well as in controls, and is associated with a significant inhibition of thrombopoietin (TPO)-primed MO-7e megakaryoblastic cells proliferation. These actions appear to be related to sOGP10-14 modulation of TGF-beta(1) synthesis and/or secretion, although a direct effect on TGF-beta receptor expression cannot be excluded. Topics: Bone Marrow; Cell Proliferation; Cytokines; Endorphins; Histones; Humans; Intercellular Signaling Peptides and Proteins; Megakaryocytes; Osteoblasts; Platelet-Derived Growth Factor; Structure-Activity Relationship; Thrombocythemia, Essential; Transforming Growth Factor beta1	2004

Article

Year

Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia.

Leukemia research, 2004, Volume: 28, Issue:10

The increase of megakaryocytes and platelets that characterizes essential thrombocythemia (ET) appears to be secondary to a deregulation of megakaryocytopoiesis. The carboxy-terminal fragment of osteogenic growth peptide (OGP10-14) promotes bone formation and hemopoiesis, while it inhibits megakaryocytopoiesis. In this paper we show that treatment with synthetic OGP10-14 (sOGP10-14) induces a significant reduction of mid and large colony-forming unit-megakaryocytes (CFU-Mk) in ET patients as well as in controls, and is associated with a significant inhibition of thrombopoietin (TPO)-primed MO-7e megakaryoblastic cells proliferation. These actions appear to be related to sOGP10-14 modulation of TGF-beta(1) synthesis and/or secretion, although a direct effect on TGF-beta receptor expression cannot be excluded.

Topics: Bone Marrow; Cell Proliferation; Cytokines; Endorphins; Histones; Humans; Intercellular Signaling Peptides and Proteins; Megakaryocytes; Osteoblasts; Platelet-Derived Growth Factor; Structure-Activity Relationship; Thrombocythemia, Essential; Transforming Growth Factor beta1

2004